20.08.2020 • News

Shell Plans Indian Petchems JV

Shell is planning to take a 50% stake and invest up to $9 billion in a petrochemical complex planned by privately held Indian oil company Nayara Energy, according to Reuters news agency.

Quoting sources familiar with the matter, Reuters said the two companies signed a Memorandum of Understanding in June to establish a joint venture. Shell has not commented on the story.

The proposed complex will be built at Vadinar, Gujarat state, where Nayara already operates a refinery, and comprises a 1.8 million t/y steam cracker and downstream units, including aromatics. Overall capacity will be 10.75 million t/y of petrochemicals with completion scheduled in five years’ time.

Nayara is already building a 450,000 t/y PP plant at Vadinar, using Unipol technology from W.R. Grace, as well as a 200,000 t/y methyl tertiary-butyl ether plant. Start-up is scheduled by the end of 2022.

Based in Mumbai, the Indian firm, formerly known as Essar Oil, is 49.13% owned by Russian energy group Rosneft.

 

Author: Elaine Burridge, Freelance Journalist

Shell plans to take a 50% stake and invest up to $9 billion in a petrochemical...
Shell plans to take a 50% stake and invest up to $9 billion in a petrochemical complex planned by Indian oil company Nayara Energy. The proposed complex will be built at Vadinar, Gujarat and comprise a 1.8 million t/y steam cracker and downstream units, including aromatics. (c) Shell

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read